许世莹,黄煜庆,郑国湾.VSIG4在恶性肿瘤诊治中的研究进展[J].肿瘤学杂志,2021,27(2):148-152.
VSIG4在恶性肿瘤诊治中的研究进展
Research Progress of VSIG4 in Diagnosis and Treatment of Malignant Tumors
投稿时间:2020-08-26  
DOI:10.11735/j.issn.1671-170X.2021.02.B011
中文关键词:  VSIG4  新型B7相关免疫球蛋白  恶性肿瘤  治疗靶点
英文关键词:VSIG4  novel B7 family-related immune globulin  malignant tumor  therapeutic target
基金项目:
作者单位
许世莹 浙江中医药大学第二临床医学院 
黄煜庆 杭州市萧山区第一人民医院 
郑国湾 浙江省人民医院 
摘要点击次数: 1027
全文下载次数: 175
中文摘要:
      摘 要:VSIG4(the protein V-set and immune globulin domain-containing 4)是一种与巨噬细胞蛋白质相关的新的B7相关免疫球蛋白的Ⅰ型跨膜蛋白,具有抑制T细胞活化的能力,也被称为CRIg(免疫球蛋白超家族)和Z39Ig,在病原体识别和清除中起关键作用。恶性肿瘤中,VSIG4的表达及VSIG4阳性T细胞的增加可能预示更高的侵袭性和复发风险。全文就VSIG4与各肿瘤间的关系作一简要概述,为VSIG4与恶性肿瘤诊治提供参考。
英文摘要:
      Abstract:The protein V-set and immunoglobulin domain containing protein 4(VSIG4),also known as CRIg and Z39Ig,is a novel type Ⅰ transmembrane protein of B7-related immunoglobulin superfamily and a negative regulator of T cell activation,which plays a key role in pathogen identification and clearance. In malignant tumors,the expression of VSIG4 and the increase of VSIG4 positive T cells may indicate higher aggressiveness and greater risk of recurrence. This article gives a brief overview of the relationship between VSIG4 and various cancer,and provides references for application of VSIG4 in the diagnosis and treatment of malignant tumors.
在线阅读   查看全文  查看/发表评论  下载PDF阅读器